Midday Report: ChemoCentryx (CCXI) Shares Climb for August 5

Equities Staff  |

ChemoCentryx Inc (NASDAQ: CCXI) shares climbed 109.13%, or $26.31 per share, as on 11:50:35 est today. After Opening the Day at $50.44, 4,616,584 shares of ChemoCentryx exchanged hands and the stock has traded between $50.79 and $50.36.  

Already the company has a YTD change of 38.51%.

ChemoCentryx anticipates its next earnings on 2022-08-08.

For technical charts, analysis, and more on ChemoCentryx visit the company profile.

About ChemoCentryx Inc

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

To get more information on ChemoCentryx Inc and to follow the company's latest updates, you can visit the company's profile page here: ChemoCentryx Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content